Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study

Hamaker, Marije E.; Seynaeve, Caroline; Nortier, J.W.R.; Wymenga, Machteld; Maartense, E.; Boven, Epie; Leeuwen-Stok, A. Elise van; Rooij, Sophia E. de; Munster, Barbara C. Van; Smorenburg, Carolien H.

doi:10.1016/j.breast.2012.12.010

Cited by 14 publications

(30 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies (8 of 13; 62%) 31,36,38,42,69,71,72,75 were based in the United States. Solid tumor malignancies were the most prevalent cancer type assessed and were the focus of 11 studies 31,36,37,69‐76 ; only 3 (23%) of 13 studies included patients with hematologic malignancies 37,72,74 . Five studies sampled patients, 37,70,72,74,76 4 sampled providers, 36,38,73,75 and 3 sampled both patients and providers 31,69,71 .…”

Section: Resultsmentioning

confidence: 99%

Older adult participation in cancer clinical trials: A systematic review of barriers and interventions

Sedrak

Freedman

Cohen

et al. 2020

CA A Cancer J Clinicians

306

200

View full text Add to dashboard Cite

Cancer is a disease of aging and, as the world's population ages, the number of older persons with cancer is increasing and will make up a growing share of the oncology population in virtually every country. Despite this, older patients remain vastly underrepresented in research that sets the standards for cancer treatments. Consequently, most of what we know about cancer therapeutics is based on clinical trials conducted in younger, healthier patients, and effective strategies to improve clinical trial participation of older adults with cancer remain sparse. For this systematic review, the authors evaluated published studies regarding barriers to participation and interventions to improve participation of older adults in cancer trials. The quality of the available evidence was low and, despite a literature describing multifaceted barriers, only one intervention study aimed to increase enrollment of older adults in trials. The findings starkly amplify the paucity of evidence-based, effective strategies to improve participation of this underrepresented population in cancer trials. Within these limitations, the authors provide their opinion on how the current cancer research infrastructure must be modified to accommodate the needs of older patients. Several underused solutions are offered to expand clinical trials to include older adults with cancer. However, as currently constructed, these recommendations alone will not solve the evidence gap in geriatric oncology, and efforts are needed to meet older and frail adults where they are by expanding clinical trials designed specifically for this population and leveraging real-world data.

show abstract

Section: Resultsmentioning

confidence: 99%

Older adult participation in cancer clinical trials: A systematic review of barriers and interventions

Sedrak

Freedman

Cohen

et al. 2020

CA A Cancer J Clinicians

306

200

View full text Add to dashboard Cite

show abstract

“…Other barriers to enrollment of older patients exist, such as the fact that older patients may not be as willing to participate in trials, particularly when this will involve random assignment of a treatment regimen, as is often the case in clinical trials [21][22][23][24]. However, a study on the attitudes of older patients toward enrolment in clinical trials demonstrates that, despite initial hesitation due to randomization, more than 75% of patients were willing to participate after additional explanation of the trial process [18].…”

Section: Discussionmentioning

confidence: 99%

Exclusion of Older Patients From Ongoing Clinical Trials for Hematological Malignancies: An Evaluation of the National Institutes of Health Clinical Trial Registry

2014

View full text Add to dashboard Cite

Introduction. Cancer societies, research cooperatives, and countless publications have urged the development of clinical trials that facilitate the inclusion of older patients and those with comorbidities. We set out to determine the characteristics of currently recruiting clinical trials with hematological patients to assess their inclusion and exclusion of elderly patients. Methods. The NIH clinical trial registry was searched on July 1, 2013, for currently recruiting phase I, II or III clinical trials with hematological malignancies. Trial characteristics and study objectives were extracted from the registry website. Results. Although 5% of 1,207 included trials focused exclusively on elderly or unfit patients, 69% explicitly or implicitly excluded older patients. Exclusion based on age was seen in 27% of trials, exclusion based on performance status was seen in 16%, and exclusion based on stringent organ function

show abstract

“…Oral administration of capecitabine is recommended as a standard salvage treatment although adverse reactions such as hand-foot syndrome and gastrointestinal side effects restrict its clinical application [5,6]. Some studies [7,8] have demonstrated significant effects achieved after a single treatment with S-1, with minimal adverse reactions.…”

Section: Introductionmentioning

confidence: 99%

Comparison of capecitabine and tegafur/gimeracil/oteracil (S-1) in the treatment of advanced breast carcinoma in the elderly

Zheng¹,

Jin²,

Liu³

2018

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study

Cited by 14 publications

References 17 publications

Older adult participation in cancer clinical trials: A systematic review of barriers and interventions

Older adult participation in cancer clinical trials: A systematic review of barriers and interventions

Exclusion of Older Patients From Ongoing Clinical Trials for Hematological Malignancies: An Evaluation of the National Institutes of Health Clinical Trial Registry

Comparison of capecitabine and tegafur/gimeracil/oteracil (S-1) in the treatment of advanced breast carcinoma in the elderly

Contact Info

Product

Resources

About